Literature DB >> 17626785

Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration.

Anna Maria Pugliese1, Elisabetta Coppi, Rosaria Volpini, Gloria Cristalli, Renato Corradetti, Lak Shin Jeong, Kenneth A Jacobson, Felicita Pedata.   

Abstract

The role of adenosine A3 receptors in synaptic transmission under severe (7 min) and shorter (2-5 min) ischemic conditions, obtained by oxygen and glucose deprivation (OGD), was investigated in rat hippocampal slices. The effects of selective A3 agonists or antagonists were examined on field excitatory postsynaptic potentials (fEPSPs) extracellularly recorded at the dendritic level of the CA1 pyramidal region. The novel, selective A3 antagonist LJ1251 ((2R,3R,4S)-2-(2-chloro-6-(3-iodobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol, 0.1-10 nM) protected hippocampal slices from irreversible fEPSP depression induced by severe OGD and prevented or delayed the appearance of anoxic depolarization. Similar results were obtained when severe OGD was carried out with a long, receptor-desensitizing exposure to various selective A3 agonists: 5'-N-methylcarboxamidoadenosine derivatives Cl-IB-MECA (N6-(3-iodobenzyl)-2-chloro), VT72 (N6-methoxy-2-phenylethynyl), VT158 (N6-methoxy-2-phenylethynyl), VT160 (N6-methoxy-2-(2-pyridinyl)-ethynyl), and VT163 (N6-methoxy-2-p-acetylphenylethynyl) and AR132 (N6-methyl-2-phenylethynyladenosine). The selective A3 antagonist MRS1523 (3-propyl-6-ethyl-5-[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine carboxylate, 100 nM) reduced fEPSP depression evoked by 2-min OGD and induced a faster recovery of fEPSP amplitude after 5-min OGD. Similar results were obtained for 2- or 5-min OGD applied in the presence of each of the A3 agonists tested. Shorter exposure to A3 agonists significantly delayed the recovery of fEPSP amplitude after 5-min OGD. This indicates that A3 receptors, stimulated by selective A3 agonists, undergo desensitization during OGD. It is inferred that CA1 hippocampal A3 receptors stimulated by adenosine released during brief ischemia (2 and 5 min) might exert A1-like protective effects on neurotransmission. Severe ischemia would transform the A3 receptor-mediated effects from protective to injurious.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17626785      PMCID: PMC2000832          DOI: 10.1016/j.bcp.2007.06.003

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  48 in total

1.  Subtype-specific kinetics of inhibitory adenosine receptor internalization are determined by sensitivity to phosphorylation by G protein-coupled receptor kinases.

Authors:  G Ferguson; K R Watterson; T M Palmer
Journal:  Mol Pharmacol       Date:  2000-03       Impact factor: 4.436

2.  Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation.

Authors:  A M Sebastião; A de Mendonca; T Moreira; J A Ribeiro
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

3.  Effect of A2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat hippocampal slices.

Authors:  S Latini; F Bordoni; R Corradetti; G Pepeu; F Pedata
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

4.  Agonist-induced internalization and recycling of the human A(3) adenosine receptors: role in receptor desensitization and resensitization.

Authors:  M L Trincavelli; D Tuscano; P Cecchetti; A Falleni; L Benzi; K N Klotz; V Gremigni; F Cattabeni; A Lucacchini; C Martini
Journal:  J Neurochem       Date:  2000-10       Impact factor: 5.372

5.  Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices.

Authors:  S Latini; F Bordoni; F Pedata; R Corradetti
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

6.  Modulation of the rat hippocampal dinucleotide receptor by adenosine receptor activation.

Authors:  Miguel Díaz-Hernández; M Fátima Pereira; Jesús Pintor; Rodrigo A Cunha; J A Ribeiro; María Teresa Miras-Portugal
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

Review 7.  Adenosine in the central nervous system: release mechanisms and extracellular concentrations.

Authors:  S Latini; F Pedata
Journal:  J Neurochem       Date:  2001-11       Impact factor: 5.372

Review 8.  Medicinal chemistry of adenosine A3 receptor ligands.

Authors:  Christa E Müller
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

9.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

10.  Investigations into the adenosine outflow from hippocampal slices evoked by ischemia-like conditions.

Authors:  F Pedata; S Latini; A M Pugliese; G Pepeu
Journal:  J Neurochem       Date:  1993-07       Impact factor: 5.372

View more
  18 in total

Review 1.  Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

Authors:  Kenneth A Jacobson; Athena M Klutz; Dilip K Tosh; Andrei A Ivanov; Delia Preti; Pier Giovanni Baraldi
Journal:  Handb Exp Pharmacol       Date:  2009

2.  CXCL16 orchestrates adenosine A3 receptor and MCP-1/CCL2 activity to protect neurons from excitotoxic cell death in the CNS.

Authors:  Maria Rosito; Cristina Deflorio; Cristina Limatola; Flavia Trettel
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

3.  Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death.

Authors:  Clotilde Lauro; Raffaela Cipriani; Myriam Catalano; Flavia Trettel; Giuseppina Chece; Valentina Brusadin; Letizia Antonilli; Nico van Rooijen; Fabrizio Eusebi; Bertil B Fredholm; Cristina Limatola
Journal:  Neuropsychopharmacology       Date:  2010-03-03       Impact factor: 7.853

4.  A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats.

Authors:  In-Young Choi; Jae-Chul Lee; Chung Ju; Sunyoung Hwang; Geum-Sil Cho; Hyuk Woo Lee; Won Jun Choi; Lak Shin Jeong; Won-Ki Kim
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

Review 5.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.

Authors:  Kenneth A Jacobson; Stefania Merighi; Katia Varani; Pier Andrea Borea; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Romeo Romagnoli; Pier Giovanni Baraldi; Antonella Ciancetta; Dilip K Tosh; Zhan-Guo Gao; Stefania Gessi
Journal:  Med Res Rev       Date:  2017-07-06       Impact factor: 12.944

6.  Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant.

Authors:  Rebecca L Williams-Karnesky; Mary P Stenzel-Poore
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

7.  Adenosine neuromodulation and traumatic brain injury.

Authors:  T A Lusardi
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

8.  The adenosine A2A receptor antagonist ZM241385 enhances neuronal survival after oxygen-glucose deprivation in rat CA1 hippocampal slices.

Authors:  A M Pugliese; C Traini; S Cipriani; M Gianfriddo; T Mello; M G Giovannini; A Galli; F Pedata
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

Review 9.  Ionotropic receptors and ion channels in ischemic neuronal death and dysfunction.

Authors:  Nicholas L Weilinger; Valentyna Maslieieva; Jennifer Bialecki; Sarup S Sridharan; Peter L Tang; Roger J Thompson
Journal:  Acta Pharmacol Sin       Date:  2012-08-06       Impact factor: 6.150

Review 10.  The adenosine kinase hypothesis of epileptogenesis.

Authors:  Detlev Boison
Journal:  Prog Neurobiol       Date:  2007-12-23       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.